Skip to main content
GSK plc
Healthcare · Drug Manufacturers - General
Made on Jul 7, 2026
Price at call $53.09
6-month call Bull +14.6%
Target by Jan 2027 $60.87
Great value below $48.00
Model v0.3.0

Projection vs Actual (6M history + forecast)

Our straight 6-month prediction (bold) with a textured realism line, and the actual price overlaid from the prediction date forward.

Forecast

One directional 6-month call and the six monthly points we'll be scored against. Predicted Jul 7, 2026 5:17 am
Bull GSK trends higher to $60.87 (+14.6% from $53.09) by Jan 2027.
Monthmonths after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $53.09 at call
Prediction made Jul 7, 2026 $53.09 at call
M1 Aug 7, 2026 $54.39 +2.4%
What actually happened: closed $52.17 on Aug 6, 2026 = -1.7% vs the call (predicted +2.5%)  ·  direction HIT (called flat, was flat)  ·  off by 4.2 pp  ·  accuracy 8/10  ·  S&P +2.8% over the same window — beat it
M2 Sep 7, 2026 $55.68 +4.9%
M3 Oct 7, 2026 $56.98 +7.3%
M4 Nov 7, 2026 $58.27 +9.8%
M5 Dec 7, 2026 $59.57 +12.2%
M6 Jan 7, 2027 $60.87 +14.6%

Deserved value (DCF/composite) is $75.83; over 6 months we project closing only part-way to it (reach 34.2%). Value-only — see Not Yet Modeled below.

Weaknesses

0 blocking · 0 degraded · 1 note — follow the chain top-down (cause → effect).
  • Note
    Valuation anchor absent: dcf.
    anchor:dcf

Equation Inputs

Everything feeding the v0.3.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$53.09
Composite fair value$70.08
Signal-adjusted fair value$74.28
DCF fair value
Anchored-PE fair value$72.34
Buy-below (value lens)$48.00
Value net score+43
Value confidence6 / 10
Quality net score+41
Memo confidence6 / 10
Deserved value (base)$70.08
Quality tilt+8.2%
Deserved value (used)$75.83
Coherence (value × quality)1.00

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 29.9%  3m 27.2%  6m 28.0%  
Daily σ (realism noise)1.7%
Beta vs S&P 500 1m -0.17  3m 0.14  5m 0.27  
Trailing 6-month return8.3%

Knobs (equation params)

Deserved wt · DCF0.5
Quality tilt cap (±)0.2
Horizon reach (6mo)0.45
Coherence floor (conflict)0.5
Conviction gain / pt0.06
Realism mean-reversion φ0.85
Conviction floor0.4
Deserved wt · composite0.5
Realism vol window3m
Neutral band (%)5
Horizon (months)6
Realism σ fallback0.015

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.3.0 #6bd904191719

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Jul 7, 2026 freshest GSK-20260707-030002-147a
ext-forensic-memo Jul 7, 2026 freshest ext-GSK-20260707-045654-2bdd
ext-lens-quality Jul 7, 2026 freshest ext-GSK-20260707-045654-2bdd
ext-lens-value Jul 7, 2026 freshest ext-GSK-20260707-045654-2bdd
scenario-valuation Jul 7, 2026 freshest GSK-20260707-030002-147a
valuation-synthesis Jul 7, 2026 freshest GSK-20260707-030002-147a

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

2 frozen snapshots — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Aug 9, 2026 v0.6.0 Bear $52.96 $49.80 -6.0% Feb 2027 view
Jul 7, 2026 v0.3.0 Bull $53.09 $60.87 +14.6% Jan 2027 viewing

Not Yet Modeled

What this v0.3.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Signal-adjusted fair value ($74.28) — the red-flag-adjusted anchor isn't the primary input yet (we use the raw DCF/composite blend, which double-counts DCF).
  • Recent momentum / drift — the line takes off straight; the trailing 6-month move (8.3%) doesn't bend the slope.
  • Market beta — computed (1–5mo) for context but does not condition the path.
  • Earnings dates, catalysts, and known events — not modeled.
  • Macro regime & sector rotation — not modeled.
  • Horizon is a fixed 6-month assumption, not a modeled time-to-target.
  • Outcome scoring — predictions aren't yet graded against realized price once the evaluation date passes.